Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children

Justino, Maria Cleonice Aguiar; Araújo, Eliete da Cunha; Doorn, Leen–Jan van; Oliveira, Consuelo Silva de; Gabbay, Yvone Benchimol; Mascarenhas, Joana D’Arc Pereira; Miranda, Yllen; Guerra, Sylvia de Fátima dos Santos; Silva, Veronilce Borges da; Linhares, Alexandre da Costa

doi:10.1590/s0074-02762012000700002

Cited by 24 publications

(12 citation statements)

References 34 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rotarix™, an orally administered vaccine, is used widely to protect from gastroenteritis and reduce its occurrence after hospitalization. 86 , 87 A clinical study showed that after one month of a two-dose series, 86.5% of 787 recipients of Rotarix were seroconverted compared with 6.7% of placebo recipients. A pentavalent vaccine, RotaTeq, was also shown to protect against rotavirus gastroenteritis at different levels of severity by increased IgA seroconversion.…”

Section: Licensed Oral Vaccinesmentioning

confidence: 99%

Noninvasive vaccination against infectious diseases

Zheng

Díaz-Arévalo

Guan

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The development of a successful vaccine, which should elicit a combination of humoral and cellular responses to control or prevent infections, is the first step in protecting against infectious diseases. A vaccine may protect against bacterial, fungal, parasitic, or viral infections in animal models, but to be effective in humans there are some issues that should be considered, such as the adjuvant, the route of vaccination, and the antigen-carrier system. While almost all licensed vaccines are injected such that inoculation is by far the most commonly used method, injection has several potential disadvantages, including pain, cross contamination, needlestick injury, under- or overdosing, and increased cost. It is also problematic for patients from rural areas of developing countries, who must travel to a hospital for vaccine administration. Noninvasive immunizations, including oral, intranasal, and transcutaneous administration of vaccines, can reduce or eliminate pain, reduce the cost of vaccinations, and increase their safety. Several preclinical and clinical studies as well as experience with licensed vaccines have demonstrated that noninvasive vaccine immunization activates cellular and humoral immunity, which protect against pathogen infections. Here we review the development of noninvasive immunization with vaccines based on live attenuated virus, recombinant adenovirus, inactivated virus, viral subunits, virus-like particles, DNA, RNA, and antigen expression in rice in preclinical and clinical studies. We predict that noninvasive vaccine administration will be more widely applied in the clinic in the near future.

show abstract

Section: Licensed Oral Vaccinesmentioning

confidence: 99%

Noninvasive vaccination against infectious diseases

Zheng

Díaz-Arévalo

Guan

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Both vaccines are recommended by the World Health Organization, have been used in several countries and studies have demonstrated a significant reduction of hospitalisation and mortality due to RV gastroenteritis (Justino et al 2012, Lopman et al 2012, Soares-Weiser et al 2012). Brazil was one of the first countries to introduce universal vaccination against RVA, Rotarix ® , which has been provided free through the public health system since March of 2006.…”

mentioning

confidence: 99%

Acute gastroenteritis and enteric viruses in hospitalised children in southern Brazil: aetiology, seasonality and clinical outcomes

Raboni

Damasio

Ferreira

et al. 2014

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Viral acute gastroenteritis (AG) is a significant cause of hospitalisation in children younger than five years. Group A rotavirus (RVA) is responsible for 30% of these cases. Following the introduction of RVA immunisation in Brazil in 2006, a decreased circulation of this virus has been observed. However, AG remains an important cause of hospitalisation of paediatric patients and only limited data are available regarding the role of other enteric viruses in these cases. We conducted a prospective study of paediatric patients hospitalised for AG. Stool samples were collected to investigate human adenovirus (HAdV), RVA, norovirus (NoV) and astrovirus (AstV). NoV typing was performed by nucleotide sequencing and phylogenetic analysis. From the 225 samples tested, 60 (26%) were positive for at least one viral agent. HAdV, NoV, RVA and AstV were detected in 16%, 8%, 6% and 0% of the samples, respectively. Mixed infections were found in nine patients: HAdV/RVA (5), HAdV/NoV (3) and HAdV/NoV/RVA (1). The frequency of fever and lymphocytosis was significantly higher in virus-infected patients. Phylogenetic analysis of NoV indicated that all of these viruses belonged to genotype GII.4. The significant frequency of these pathogens in patients with AG highlights the need to routinely implement laboratory investigations.

show abstract

“…Currently, there are two oral, live attenuated RV vaccines: Rotarix (GlaxoSmithKline Biologicals, Rixensart, Belgium) and RotaTeq (Merck & Co., Inc., Whitehouse Station, NJ, USA). The WHO has recently recommended the inclusion of rota virus vaccination of infants in all national immunization programs (32). Although RV vaccines have not been introduced in the national vaccination programs in Turkey, both vaccines are commercially available (15).…”

Section: Discussionmentioning

confidence: 99%

Emergence of rotavirus G9 in 2012, as the dominant genotype in Turkish children with diarrhea, in a university hospital in Ankara

Koçak

Aydın

Matsumoto

et al. 2019

Revista Romana De Medicina De Laborator

View full text Add to dashboard Cite

Introduction: Rotavirus infection is a major cause of morbidity and mortality in infants and young children with diarrhea throughout the world. Material and Methods: In this study, we aimed to determine the detection rate of rotavirus infection in 181 children less than 5 years of age presenting with acute gastroenteritis and admitted to a tertiary care hospital in Ankara, Turkey, from April to November 2012. We documented the epidemiological data by elucidating the prevalent genotypes. Stool specimens were collected, and rotavirus antigen in the samples was detected using ELISA. G and P genotypes were determined by RT-PCR via type specific primers. The nucleotide sequence of the concerned genes was determined by Sanger sequencing and phylogenetic analysis was performed by neighbor-joining method. Results: Of the 181 samples, 28 (15.5%) were positive for the rotavirus antigen. Twenty-seven samples were positive for G genotypes and 21 were positive for P genotypes. Genotypes G1 (7.1%), G2 (7.1%), G3 (7.1%), G4 (3.6%), G9 (71.5%) and P4 (3.6%), P8 (71.4%) were identified. Genotype G9P[8] (50%) was predominant in the combination of G and P genotypes. Most of the G9 strains of this study formed an independent cluster in Lineage III, except two strains which clustered with an Ethiopian G9 strain of 2012. Conclusions: It seems that during 2012 season, genotype G9P[8] increased significantly in Ankara due to a new circulating strain of G9.

show abstract

Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children

Cited by 24 publications

References 34 publications

Noninvasive vaccination against infectious diseases

Noninvasive vaccination against infectious diseases

Acute gastroenteritis and enteric viruses in hospitalised children in southern Brazil: aetiology, seasonality and clinical outcomes

Emergence of rotavirus G9 in 2012, as the dominant genotype in Turkish children with diarrhea, in a university hospital in Ankara

Contact Info

Product

Resources

About